[¼Dieser Fehler ist einzig und allein mein Fehler« - Political Communication in the Sign of the Corona Pandemic]. / ¼Dieser Fehler ist einzig und allein mein Fehler« ­ Politische Kommunikation im Zeichen der Corona-Pandemie.

In the current COVID pandemic, the communication by political actors addressing the public is an important means to justify and legitimize political decisions. This contribution examines political communication aimed at the public at the example of addresses and government declarations by Chancellor of Austria Sebastian Kurz and Chancellor of Germany Angela Merkel during March 2020 and March 2021. When occasion and the intended goal of the actors' speeches are same, clear differences become visible in the concrete linguistic realization of the addresses and government declarations, yet also similarities can be seen. The contribution focuses particularly on the argumentative structure, speech acts and associated practices of positioning and addressing as well as communicative strategies in order to elaborate both similarities and differences between the speeches.

Very early reduction in efficacy of botulinum toxin therapy for cervical dystonia in patients with subsequent secondary treatment failure: a retrospective analysis.

The objective of this study was to estimate the probability of development of partial secondary treatment failure (PSTF) in patients with cervical dystonia (CD) who had been treated over up to 9 years with repetitive intramuscular injections of botulinum neurotoxin type A (BoNT/A). The temporal course of treatment response in patients in whom PSTF was detected retrospectively was compared to patients with a normal clinical response. For this purpose, charts of all CD patients treated in our outpatient clinic between 1988 and 2001 were retrospectively analyzed. Extracted data included time of all injections, dose per visit, disease severity measured by TSUI scores, and time of determination of neutralizing antibodies. Final data analysis using a special formal definition of PSTF was based on charts of 568 patients having exclusively been treated with abobotulinumtoxinA. PSTF onset was observed in our CD cohort during the entire treatment period analyzed, with no clustering at any time point. Probability to develop PSTF was 14.5 % in 9 years. Thus, mean PSTF incidence was 1.6 % per year. The mean TSUI score of patients with retrospectively defined PSTF (n = 33) became already significantly worse after the second injection when compared with the group without PSTF (n = 535). Our data indicate that clinical response in patients developing PSTF later on differs from that of patients without PSTF already very early in the course of botulinum neurotoxin type A treatment, and that PSTF remains undetected at this early stage. Reduced response may therefore be present in a number of CD patients who think they still respond normally to continuous BoNT/A treatment.